Biopharma: EHA 2026 MPN Planner Covering Oral Presentations, Posters, and Publications

Research evidence excerpt

Biopharma: EHA 2026 MPN Planner Covering Oral Presentations, Posters, and Publications

Truist Securities

Lilly Momelotinib FROM IMMUNOSUPPRESSION TO IMMUNE REBALANCING: EARLY IMMUNOLOGICAL EFFECTS OF MOMELOTINIB IN PB3418 Publication MF >5pt changes in immunological

MYELOFIBROSIS parameters inc. CD4+CD197+ etc.

Lilly / Suzhou Momelotinib / Gecacitinib INDIRECT TREATMENT COMPARISON: GECACITINIB VS. PACRITINIB, MOMELOTINIB, AND FEDRATINIB IN FIRST-LINE PS1993 Poster 1L MF Gecacitinib superior monotx to

MYELOFIBROSIS momelotinib and pacritinib

earlier initiation of treatment

Lilly Momelotinib OUTCOMES WITH MOMELOTINIB IN PATIENTS WITH INTERMEDIATE-1– VS INTERMEDIATE-2–/HIGH-RISK MYELOFIBROSIS: POST PS1995 Poster MF before progression to int-2–/high-

HOC ANALYSES OF THE PHASE 3 SIMPLIFY-1 AND MOMENTUM TRIALS risk disease may be associated with

better outcomes

Lilly AJ1-11095 RESULTS OF AJX-101, A PHASE 1 CLINICAL TRIAL OF THE TYPE II JAK2 INHIBITOR AJ1-11095, IN PATIENTS WITH MYELOFIBROSIS S218 Oral 2L MF 75mg dose for dose epansion,

WHO HAVE BEEN FAILED BY A TYPE I JAK2 INHIBITOR comparable SVR35

Takeda / Keros Elritercept ELRISE: A PHASE 3 STUDY OF ELRITERCEPT VS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAÏVE ADULTS PB3085 Publication 1L LR-MDS and TDA Methods paper

WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND TRANSFUSION-DEPENDENT ANEMIA

BMS Lupatercept EFFICACY EVALUATION OF LUSPATERCEPT IN MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS WITH SF3B1 MUTATIONS WHO Pb3098 Publication r/r MDS

HAVE FAILED HYPOMETHYLATING AGENT THERAPY

BMS Lupatercept EXTENDED FOLLOW-UP OF LUSPATERCEPT TREATMENT IN LOWER-RISK, TRANSFUSION-DEPENDENT MYELODYSPLASTIC PB3096 Publication LR-MDS

SYNDROMES WITH RING SIDEROBLASTS: HEMATOLOGIC RESPONSE AND MULTILINEAGE EFFECTS